NO317873B1 - Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning. - Google Patents

Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning. Download PDF

Info

Publication number: NO317873B1
Authority: NO; Norway
Prior art keywords: iron; dialysis; patients; dialysate; pyrophosphate
Prior art date: 1996-12-31

Application number

NO19993235A

Other languages

English (en)

Norwegian (no)

Other versions

NO993235L (no

NO993235D0 (no

Inventor

Ajay Gupta

Original Assignee

Ajay Gupta

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-31

Filing date

1999-06-29

Publication date

2004-12-27

1996-12-31 Priority claimed from US08/775,595 external-priority patent/US6689275B1/en

1999-06-29 Application filed by Ajay Gupta filed Critical Ajay Gupta

1999-06-29 Publication of NO993235D0 publication Critical patent/NO993235D0/no

1999-08-27 Publication of NO993235L publication Critical patent/NO993235L/no

2004-12-27 Publication of NO317873B1 publication Critical patent/NO317873B1/no

Links

CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 title claims abstract description 69
239000000385 dialysis solution Substances 0.000 title claims abstract description 43
238000000034 method Methods 0.000 title claims abstract description 33
239000000203 mixture Substances 0.000 title claims description 20
238000002360 preparation method Methods 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 500
229910052742 iron Inorganic materials 0.000 claims abstract description 236
238000000502 dialysis Methods 0.000 claims abstract description 121
238000001631 haemodialysis Methods 0.000 claims abstract description 55
230000000322 hemodialysis Effects 0.000 claims abstract description 54
239000012141 concentrate Substances 0.000 claims description 33
239000000243 solution Substances 0.000 claims description 30
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
238000001802 infusion Methods 0.000 abstract description 9
150000001875 compounds Chemical class 0.000 abstract description 7
235000007144 ferric diphosphate Nutrition 0.000 abstract description 7
239000011706 ferric diphosphate Substances 0.000 abstract description 7
229940036404 ferric pyrophosphate Drugs 0.000 abstract description 7
230000008569 process Effects 0.000 abstract description 5
238000001990 intravenous administration Methods 0.000 description 59
210000002966 serum Anatomy 0.000 description 50
102000004338 Transferrin Human genes 0.000 description 47
108090000901 Transferrin Proteins 0.000 description 47
239000012581 transferrin Substances 0.000 description 47
108090000394 Erythropoietin Proteins 0.000 description 32
102000003951 Erythropoietin Human genes 0.000 description 31
210000004369 blood Anatomy 0.000 description 31
239000008280 blood Substances 0.000 description 31
229940105423 erythropoietin Drugs 0.000 description 31
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 31
238000002560 therapeutic procedure Methods 0.000 description 29
238000011282 treatment Methods 0.000 description 29
102000001554 Hemoglobins Human genes 0.000 description 27
108010054147 Hemoglobins Proteins 0.000 description 27
206010022971 Iron Deficiencies Diseases 0.000 description 25
210000002381 plasma Anatomy 0.000 description 25
102000008857 Ferritin Human genes 0.000 description 24
108050000784 Ferritin Proteins 0.000 description 24
238000008416 Ferritin Methods 0.000 description 24
238000012423 maintenance Methods 0.000 description 20
241000283973 Oryctolagus cuniculus Species 0.000 description 18
239000012528 membrane Substances 0.000 description 17
150000002506 iron compounds Chemical class 0.000 description 16
238000012546 transfer Methods 0.000 description 15
210000004379 membrane Anatomy 0.000 description 14
238000004458 analytical method Methods 0.000 description 12
230000008859 change Effects 0.000 description 10
238000012384 transportation and delivery Methods 0.000 description 10
208000020832 chronic kidney disease Diseases 0.000 description 9
230000002950 deficient Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000005534 hematocrit Methods 0.000 description 9
210000004303 peritoneum Anatomy 0.000 description 9
102000008133 Iron-Binding Proteins Human genes 0.000 description 8
108010035210 Iron-Binding Proteins Proteins 0.000 description 8
230000000694 effects Effects 0.000 description 7
231100000331 toxic Toxicity 0.000 description 7
230000002588 toxic effect Effects 0.000 description 7
235000005911 diet Nutrition 0.000 description 6
230000037213 diet Effects 0.000 description 6
238000009792 diffusion process Methods 0.000 description 6
201000000523 end stage renal failure Diseases 0.000 description 6
230000002489 hematologic effect Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000001154 acute effect Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
208000028208 end stage renal disease Diseases 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
239000008213 purified water Substances 0.000 description 5
210000001995 reticulocyte Anatomy 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000000108 ultra-filtration Methods 0.000 description 5
230000003442 weekly effect Effects 0.000 description 5
208000037157 Azotemia Diseases 0.000 description 4
206010065973 Iron Overload Diseases 0.000 description 4
210000000683 abdominal cavity Anatomy 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
208000007502 anemia Diseases 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
235000011180 diphosphates Nutrition 0.000 description 4
239000000004 hemodialysis solution Substances 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
235000016709 nutrition Nutrition 0.000 description 4
230000004044 response Effects 0.000 description 4
208000009852 uremia Diseases 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
208000013038 Hypocalcemia Diseases 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
208000022831 chronic renal failure syndrome Diseases 0.000 description 3
238000011067 equilibration Methods 0.000 description 3
150000003278 haem Chemical class 0.000 description 3
238000002615 hemofiltration Methods 0.000 description 3
230000000705 hypocalcaemia Effects 0.000 description 3
230000036543 hypotension Effects 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
235000020796 iron status Nutrition 0.000 description 3
MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
239000011707 mineral Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
210000000504 visceral peritoneum Anatomy 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920000388 Polyphosphate Polymers 0.000 description 2
241000700159 Rattus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
210000003815 abdominal wall Anatomy 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000003433 contraceptive agent Substances 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002706 hydrostatic effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229940090441 infed Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
210000000505 parietal peritoneum Anatomy 0.000 description 2
210000003200 peritoneal cavity Anatomy 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
229920002492 poly(sulfone) Polymers 0.000 description 2
239000001205 polyphosphate Substances 0.000 description 2
235000011176 polyphosphates Nutrition 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000003307 reticuloendothelial effect Effects 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000037317 transdermal delivery Effects 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
RLSFDUAUKXKPCZ-UITAMQMPSA-N (z)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)but-2-en-1-one Chemical compound C1CN(C(=NN=2)C(F)(F)F)C=2CN1C(=O)\C=C(/N)CC1=CC(F)=C(F)C=C1F RLSFDUAUKXKPCZ-UITAMQMPSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
GEZAUFNYMZVOFV-UHFFFAOYSA-J 2-[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetan-2-yl)oxy]-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetane 2-oxide Chemical compound [Sn+2].[Sn+2].[O-]P([O-])(=O)OP([O-])([O-])=O GEZAUFNYMZVOFV-UHFFFAOYSA-J 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000003241 Fat Embolism Diseases 0.000 description 1
CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 1
206010016803 Fluid overload Diseases 0.000 description 1
101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
206010027417 Metabolic acidosis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010034650 Peritoneal adhesions Diseases 0.000 description 1
206010034665 Peritoneal fibrosis Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
JOJMQRPFXIKGJG-UHFFFAOYSA-N acetic acid;carbonic acid Chemical compound CC(O)=O.OC(O)=O JOJMQRPFXIKGJG-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
229940008201 allegra Drugs 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000022400 anemia due to chronic disease Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000000823 artificial membrane Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
238000007816 calorimetric assay Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
231100000060 cardiovascular toxicity Toxicity 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007485 conventional hemodialysis Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000007728 cost analysis Methods 0.000 description 1
-1 cupraphan Polymers 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000004079 fireproofing Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
201000005991 hyperphosphatemia Diseases 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052816 inorganic phosphate Inorganic materials 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
210000002311 liver mitochondria Anatomy 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
150000004690 nonahydrates Chemical group 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
235000003715 nutritional status Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003330 peritoneal dialysis fluid Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229960003351 prussian blue Drugs 0.000 description 1
239000013225 prussian blue Substances 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
231100000828 respiratory toxicity Toxicity 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000002151 serous membrane Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000013589 supplement Substances 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229910001432 tin ion Inorganic materials 0.000 description 1
230000003868 tissue accumulation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
External Artificial Organs (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO19993235A 1996-12-31 1999-06-29 Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning. NO317873B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/775,595 US6689275B1 (en)	1996-12-31	1996-12-31	Method and pharmaceutical composition for replacing iron losses in dialysis patients
US5531597P	1997-08-07	1997-08-07
PCT/US1997/023719 WO1998029434A1 (en)	1996-12-31	1997-12-30	Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients

Publications (3)

Publication Number	Publication Date
NO993235D0 NO993235D0 (no)	1999-06-29
NO993235L NO993235L (no)	1999-08-27
NO317873B1 true NO317873B1 (no)	2004-12-27

Family

ID=26734087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19993235A NO317873B1 (no)	1996-12-31	1999-06-29	Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning.

Country Status (17)

Country	Link
EP (1)	EP0951470B1 (de)
JP (2)	JP3955639B2 (de)
AT (1)	ATE311180T1 (de)
AU (1)	AU736053B2 (de)
BR (1)	BR9713653B1 (de)
CA (1)	CA2276442C (de)
DE (1)	DE69734781T2 (de)
DK (1)	DK0951470T3 (de)
EA (1)	EA002479B1 (de)
ES (1)	ES2255115T3 (de)
NO (1)	NO317873B1 (de)
NZ (1)	NZ336319A (de)
PL (1)	PL191377B1 (de)
SI (1)	SI20151A (de)
TR (1)	TR199901518T2 (de)
WO (1)	WO1998029434A1 (de)
YU (1)	YU31299A (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5906978A (en) *	1996-08-14	1999-05-25	Hemocleanse, Inc.	Method for iron delivery to a patient by transfer from dialysate
US7670491B2 (en)	1998-10-20	2010-03-02	Advanced Renal Technologies	Buffered compositions for dialysis
ES2322689T3 (es)	1999-09-22	2009-06-25	Advanced Renal Technologies	Uso de un dializado con elevado contenido de citrato.
DE19951471A1 (de) *	1999-10-26	2001-05-03	Forssmann Wolf Georg	Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
WO2005044189A2 (en) *	2003-10-28	2005-05-19	Emory University	Dialysates and methods and systems related thereto
US8187467B2 (en) *	2003-12-30	2012-05-29	Ajay Gupta	Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion
SE0400523D0 (sv)	2004-03-01	2004-03-01	Gambro Lundia Ab	A medical solution, a method for producing said medical solution and use thereof
SE0402507D0 (sv)	2004-10-14	2004-10-14	Gambro Lundia Ab	Medicinsk lösning, förfarande för framställning och användning därav
US7586589B2 (en) *	2005-09-24	2009-09-08	Beckman Coulter, Inc.	Methods of determination of responsiveness to erythropoietin treatment
US7816404B2 (en) *	2007-07-20	2010-10-19	Rockwell Medical Technologies, Inc.	Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US7658952B2 (en) *	2007-10-11	2010-02-09	Baxter International Inc.	Dialysis solutions containing pyrophosphates
CN107080752B (zh) *	2010-04-23	2020-07-31	巴克斯特国际公司	减少或防止腹膜透析治疗期间血管钙化的方法和组合物
AU2015200995B2 (en) *	2010-04-23	2016-09-08	Vantive Health Gmbh	Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy
MX370139B (es) *	2013-02-01	2019-12-03	Charak Llc	Pirofosfato ferrico soluble (pfs) para usarse en el tratamiento de anemiay/o de la deficiencia de hierro.
JP6578293B2 (ja) *	2013-11-05	2019-09-18	ロックウェルメディカル，インコーポレイテッド	反応性が低下した患者のエリトロポエチン刺激剤の用量を減少させる方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3530216A (en) *	1967-10-05	1970-09-22	Hoffmann La Roche	Vitamin compositions comprising riboflavin-5-phosphate and ferric pyrophosphate soluble
US3911915A (en) *	1972-09-05	1975-10-14	Einstein Coll Med	Dialytic introduction of maltose into bloodstream
JPS5125238B2 (de) *	1973-08-14	1976-07-29
US4756838A (en) *	1980-02-21	1988-07-12	Veltman Preston Leonard	Preparation of dry dialysate products
JPH0696586B2 (ja) *	1987-03-17	1994-11-30	花王株式会社	ヘキソ−スリン酸第一鉄塩及びその製造法並びにこれを含有する鉄供給剤
JPH0525051A (ja) *	1991-07-19	1993-02-02	Meiji Seika Kaisha Ltd	貧血予防・治療剤
JP3167402B2 (ja) *	1992-02-25	2001-05-21	仙味エキス株式会社	鉄吸収促進組成物

1997
- 1997-12-30 EP EP97952598A patent/EP0951470B1/de not_active Expired - Lifetime
- 1997-12-30 DK DK97952598T patent/DK0951470T3/da active
- 1997-12-30 ES ES97952598T patent/ES2255115T3/es not_active Expired - Lifetime
- 1997-12-30 WO PCT/US1997/023719 patent/WO1998029434A1/en not_active Ceased
- 1997-12-30 NZ NZ336319A patent/NZ336319A/xx not_active IP Right Cessation
- 1997-12-30 SI SI9720087A patent/SI20151A/sl unknown
- 1997-12-30 AU AU56172/98A patent/AU736053B2/en not_active Expired
- 1997-12-30 AT AT97952598T patent/ATE311180T1/de active
- 1997-12-30 BR BRPI9713653-0A patent/BR9713653B1/pt not_active IP Right Cessation
- 1997-12-30 TR TR1999/01518T patent/TR199901518T2/xx unknown
- 1997-12-30 JP JP53014898A patent/JP3955639B2/ja not_active Expired - Lifetime
- 1997-12-30 DE DE69734781T patent/DE69734781T2/de not_active Expired - Lifetime
- 1997-12-30 EA EA199900609A patent/EA002479B1/ru not_active IP Right Cessation
- 1997-12-30 YU YU31299A patent/YU31299A/sh unknown
- 1997-12-30 CA CA2276442A patent/CA2276442C/en not_active Expired - Lifetime
- 1997-12-30 PL PL334437A patent/PL191377B1/pl unknown
1999
- 1999-06-29 NO NO19993235A patent/NO317873B1/no not_active IP Right Cessation
2007
- 2007-01-12 JP JP2007004535A patent/JP4753379B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP3955639B2 (ja)	2007-08-08
PL334437A1 (en)	2000-02-28
PL191377B1 (pl)	2006-05-31
NO993235L (no)	1999-08-27
DE69734781D1 (de)	2006-01-05
JP4753379B2 (ja)	2011-08-24
ES2255115T3 (es)	2006-06-16
NO993235D0 (no)	1999-06-29
AU736053B2 (en)	2001-07-26
BR9713653B1 (pt)	2013-05-21
DE69734781T2 (de)	2006-07-20
DK0951470T3 (da)	2006-03-27
CA2276442C (en)	2012-01-17
WO1998029434A1 (en)	1998-07-09
EA002479B1 (ru)	2002-06-27
EP0951470B1 (de)	2005-11-30
BR9713653A (pt)	2000-04-11
NZ336319A (en)	2000-12-22
TR199901518T2 (xx)	1999-12-21
YU31299A (sh)	2002-08-12
JP2007106775A (ja)	2007-04-26
HK1023350A1 (en)	2000-09-08
EP0951470A1 (de)	1999-10-27
ATE311180T1 (de)	2005-12-15
EP0951470A4 (de)	2003-05-02
CA2276442A1 (en)	1998-07-09
JP2002531051A (ja)	2002-09-17
EA199900609A1 (ru)	1999-12-29
AU5617298A (en)	1998-07-31
SI20151A (sl)	2000-08-31

Legal Events

Date	Code	Title	Description
2018-01-08	MK1K	Patent expired

Publication	Publication Date	Title
US6779468B1 (en)	2004-08-24	Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
JP4753379B2 (ja)	2011-08-24	血液透析及び腹膜透析患者における鉄デリバリーのための方法及び医薬組成物
US4889634A (en)	1989-12-26	Dialysate solution containing hydroxypropyl-beta-cyclodextrin and method of using same
Macdougall	2009	Evolution of iv iron compounds over the last century
Arieff et al.	1973	Brain water and electrolyte metabolism in uremia: effects of slow and rapid hemodialysis
AU2003299683B2 (en)	2008-10-02	Biocompatible dialysis fluids containing icodextrins
JP5690040B2 (ja)	2015-03-25	重炭酸塩ベースの腹膜透析溶液
Sam et al.	2006	Composition and clinical use of hemodialysates
US20050020507A1 (en)	2005-01-27	Dialysis solutions with reduced levels of glucose degradation products
EP0153164B1 (de)	1990-05-02	Lösung für die Peritonealdialyse
EP0078832A1 (de)	1983-05-18	Dialyselösung enthaltendes glycerol.
WO2001000204A1 (en)	2001-01-04	Method and pharmaceutical composition for parenteral administration of iron
JP2000504745A (ja)	2000-04-18	Ａｇｅ生成物の形成が少ない、グルコースを含んで成る溶液の腹膜透析のための使用
Parsons et al.	1975	Use of dialysis in the treatment of renal failure in liver disease
HK1023350B (en)	2006-03-03	Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
MXPA99006187A (en)	2000-05-01	Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
Feriani et al.	1993	Continuous ambulatory peritoneal dialysis with bicarbonate buffer-a pilot study
Blumenkrantz et al.	1979	Comparisons of Hemodialysis and Peritoneal Dialysis: a Review of the Literature¹
JP2019516428A (ja)	2019-06-20	透析濃縮液
Davenport	2004	Treated by Continuous Veno-Venous